RAP-219, an investigational epilepsy-derived candidate, achieved the primary goal in a mid-stage bipolar trial, according to the reported results. The trial outcome could broaden the company’s clinical development path for a program viewed by analysts as potentially large-addressable, though the data remain mid-stage and will require continued validation.